One of the obstacles for the design of clinical trials in acute and chronic graft-versus-host disease (aGVHD, cGVHD) has been that the available classification criteria were imperfect. The historic definition of aGVHD and cGVHD was based on a cutoff at day 100, which did not account for the facts that aGVHD can also occur after day 100 and that symptoms of aGVHD and cGVHD can occur simultaneously. Also, the established cGVHD severity grades 'limited' versus 'extensive' were not able to provide sufficient information on the overall extent of the disease, and they did not allow discerning patients with indication for treatment. Therefore, a new GVHD classification was proposed by a National Institutes of Health (NIH) working group. 1 According to the NIH consensus criteria (NCC) the broad category of aGVHD should include (1) classic aGVHD, occurring within 100 days after HCT or donor lymphocyte infusions (DLI), and (2) persistent, recurrent or late-onset aGVHD occurring thereafter (late aGVHD). The broad category of cGVHD should include (1) classic cGVHD, where cGVHD manifestations should be present without features of aGVHD, and (2) an overlap syndrome in which features of cGVHD and aGVHD are seen concomitantly. In addition, a new cGVHD global severity score based on individual organ assessment was developed. Several groups have published their experience with this classification, however, no validation in a single disease entity and no direct comparison of the differential impact of reduced intensity (RIC) and myeloablative conditioning (MAC) has been performed yet. This stratification seems critical, because GVHD incidence and severity strongly depend on conditioning intensity, and because graft-versus-leukemia effects may have a different relevance.
Here, we present an evaluation of 202 acute myeloid leukemia patients where GVHD was diagnosed, classified and graded according to the NCC, 1 and where patients were stratified according to conditioning intensity. All patient-, disease-and transplant-related characteristics, information on the occurrence of GVHD according to conventional criteria and follow-up information had been prospectively entered into an electronic patient registry. For classification of GVHD according to the NCC, all patient histories were revisited. All patients gave informed consent for analysis of their data, in accordance with the declaration of Helsinki.
A total of 100 patients received MAC (6 Â 2 Gy total body irradiation, 2 Â 60 mg/kg cyclophosphamide and in case of HLA-mismatch 3 Â 10 mg/kg ATG-Fresenius (ATG): n ¼ 97, other MAC: n ¼ 3) and 102 patients received RIC (6 Â 30 mg/m 2 fludarabine, 2 Â 4 mg/kg oral busulfan and 4 Â 10 mg/kg ATG: n ¼ 93, other RIC: n ¼ 9). GVHD prophylaxis consisted of cyclosporine and short course methotrexate for MAC and cyclosporine and mycophenolate mofetil for RIC.
2 DLI were a treatment option for mixed chimerism, recurrence of cytogenetic markers or for morphological relapse after reinduction chemotherapy.
When we compared pre-transplant characteristics between RIC and MAC patients, no significant differences were found in the majority of parameters (Table 1 ). However, due to our indication criteria, Karnofsky performance status in RIC patients was lower, median age was higher and consecutively Letters to the Editor their related donors were older and less recipient/donor pairs were CMV-negative. Also, RIC patients were treated more recently, they received more CD34 þ cells and DLI were given more often. As described by others, median time to leukocyte recovery was significantly shorter in RIC compared with MAC patients (14 days (range: 5-34) for RIC versus 19 days (10-42) for MAC, Po0.0001). Median time to reach full donor chimerism in the blood (60 days (14-720) for RIC versus 56 days (14-1117) for MAC, P ¼ 0.12) and in the bone marrow (100 days (28-904) for RIC versus 56 days (28-1585) for MAC, P ¼ 0.16) was not significantly different. Importantly, 5-year overall survival (OS) (48% (95% CI: 37-60%) for RIC versus 45% (35-55%) for MAC, N.S.), disease-free survival (45% (35-55%) for RIC versus 43% (33-54%) for MAC, N.S.), and cumulative incidences of relapse (39% (30-50%) for RIC versus 37% (29-48%) for MAC, N.S.) and non-relapse mortality (NRM) (18% (12-28%) for RIC versus 22% (15-32%) for MAC, N.S.) were not significantly different between the two groups, confirming earlier studies, which had shown that RIC is a viable alternative for older or more comorbid acute myeloid leukemia patients. 3 Regarding NIH-defined GVHD, we found that the cumulative incidence of classic aGVHD was significantly lower in RIC than in MAC patients ( Figure 1a ). Also, classic aGVHD occurred significantly later in the RIC cohort (31 days (range: 10-95) for RIC versus 23 days (9-86) for MAC, P ¼ 0.041). Among patients with classic aGVHD, no statistical significant differences were seen in the frequency or severity of different organ manifestations and in the overall aGVHD grade ( Table 2) . Prior studies had already described that the incidence of aGVHD is generally lower after RIC than after MAC and that it occurs later, 4, 5 however, these conclusions were based on the classical definition of aGVHD and cases occurring after day 100 could have been missed. It is interesting to note that aGVHD was less common and occurred later in our RIC cohort despite higher CD34 þ cell dose, faster leukocyte engraftment and similar kinetics of donor CD3 þ T-cell chimerism. This indicates that the most important predisposing factor for aGVHD may not be the kinetics of alloengraftment but rather the intensity of the conditioning regimen and the associated pro-inflammatory cytokine milieu and tissue damage. In agreement with this conclusion we found in multivariate Cox regression analysis that the only significant risk factor for classic aGVHD was the application of MAC (data not shown). Late aGVHD was a rare event with no significant differences between RIC and MAC patients (Figure 1b) . Most late aGVHD cases were subclassified as persistent or recurrent aGVHD (Table 2 ). When organ involvement of classic and late aGVHD was compared no significant differences were seen and also the rate of progression to cGVHD was not different (data not shown). The only significant risk factor for late aGVHD was prior classic aGVHD (data not shown), indicating that late aGVHD and classic aGVHD were not independent events in our patients.
Median time until onset of classic cGVHD was 167 days (97-718) after RIC and 259 days (88-1091) after MAC, which was not significantly different. Also, the 3-year cumulative incidence of classic cGHVD was not different for RIC and MAC patients ( Figure 1c ). Median time until the onset of overlap syndrome was 156 days (97-400) after RIC and 210 days (86-1252) after MAC, which was not significantly different. However, in contrast to classic cGVHD, the 3-year cumulative incidence of overlap syndrome was significantly lower after RIC (Figure 1d ). Organ involvement was similar after RIC and MAC, with the exception of cGVHD of the joints and fascia, which was more common after MAC (Table 2) , possibly due to a Abbreviations: aGVHD; acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; RIC, reduced intensity conditioning; MAC, myeloablative conditioning; NIH, National Institutes of Health; N.S., not significant. AGVHD was diagnosed when typical skin, liver or gastro-intestinal symptoms developed without manifestations of cGVHD. AGVHD was subclassified into classic aGVHD when first symptoms occurred within 100 days after HCT or DLI and late aGVHD when aGVHD symptoms were seen thereafter. Classic cGVHD was diagnosed when at least one diagnostic manifestation of cGVHD or one distinctive manifestation confirmed by biopsy or other pertinent test was present without presence of acute symptoms and overlap syndrome was diagnosed if there were cGVHD features concurrent with typical aGVHD features. AGVHD was graded according to the Glucksberg criteria and cGVHD was graded according to the NCC. 1 No correction for multiple testing was applied, thus P-values are not strictly confirmative. Letters to the Editor detrimental effect of total body irradiation. Significant risk factors for classic cGVHD were prior aGVHD and DLI. Significant risk factors for overlap syndrome were MAC, prior aGVHD, DLI, transplantation beyond CR1 and female-to-male transplantation (data not shown). Regarding cGVHD, most prior studies using the classical GVHD definition had found a similar incidence after RIC and MAC, 4 however, others had also described less cGVHD in RIC patients. 5 Using the NCC we now describe a lower cGVHD incidence after RIC in the subgroup of overlap syndrome, but not in classic cGVHD, which again highlights the predominant effect of the conditioning intensity on the development of aGVHD symptoms.
To determine the impact of GVHD on OS, relapse and NRM we performed a multivariate Cox regression analysis where GVHD was included as a time-dependent covariate (Table 3) . We found that classic aGVHD grade III/IV was associated with inferior OS in both RIC and MAC patients, which was due to higher NRM, confirming earlier studies that had used the classic aGVHD definition. 6 Comparable effects on OS and NRM were seen for late aGVHD in univariate analysis (data not shown), but when classic aGVHD was added to the model any prognostic value of late aGVHD was lost. Together with our findings on organ involvement and risk to progression to cGVHD, these results indicate that late aGVHD shares a similar biology and prognostic impact with classic aGVHD. This conclusion is supported by some studies on the NCC, which described higher NRM and/or inferior survival in patients, with late aGVHD compared with those with classic cGVHD or overlap syndrome. 7, 8 Nonetheless, other reports could not confirm such an effect. 9 For cGVHD we found that moderate forms had a beneficial effect in both RIC and MAC patients, whereas severe forms were somewhat beneficial after MAC, but detrimental after RIC, possibly due to the older age and reduced performance status in the RIC cohort. Owing to limited sample size we were not able to evaluate the different global severity scores of classic and overlap cGVHD with sufficient statistical power, however, across all severity scores we found a significant negative survival impact of overlap versus classic cGVHD in MAC patients and a negative trend in RIC patients, again highlighting the unfavorable prognostic impact of aGVHD symptoms.
To our knowledge this study represents the first direct comparison of the influence of RIC and MAC on the natural history and prognostic impact of NIH-defined GVHD and it is also the first report which evaluated NIH-defined GVHD in a single disease entity.
However, our analysis is limited by the low patient numbers in some subgroups and by the fact that some characteristics differed between RIC and MAC patients. Importantly, the application of ATG in all RIC patients, but in MAC patients only in case of HLA-mismatch, may have lowered the incidence of aGVHD and overlap syndrome in the RIC group. DLI were given more frequently to RIC patients, but we accounted for this bias in a subanalysis where application of DLI was treated as a competing event. In this analysis, the lower rate of aGVHD and overlap syndrome after RIC was even more prominent.
In summary, our study confirms the feasibility and clinical relevance of the NCC, and it demonstrates a differential impact of RIC and MAC on the characteristics of NIH-defined GVHD. Our study also confirms the negative prognostic impact of severe aGVHD and the potential benefit of cGVHD. In addition, our study indicates that late aGVHD shares a similar biology and prognostic impact with classic aGVHD and consequently this new category should allow a better allocation of patients to therapies and clinical trials. Also, the new category of overlap syndrome appears clinically meaningful as it had a negative prognostic impact compared with classic cGVHD. Trials are underway in the US and Europe, which prospectively evaluate the feasibility and true prognostic value of the new NIH classification. Virchow-Klinikum, Berlin, Germany; Foci of iron deposition in the perinuclear mitochondria of erythroid precursors, called ring sideroblasts (RS), can be seen in acquired and congenital cases of anemia. In many patients with myelodysplastic/myeloproliferative neoplasm (MDS/MPN) and myelodysplastic syndrome (MDS), various frequencies of RS can be found when stained with Prussian blue. 1 The finding of 415% RS together with the appropriate morphologic and cytogenetic criteria is consistent with the diagnosis of refractory anemia with RS (RARS).
2 RS can be also found in a form of MDS/MPN called refractory anemia with RS associated with marked thrombocytosis (RARS-T). Patients with RARS and RARS-T were also found to have mutations in JAK2, MPL, TET2 and ASXL1. [3] [4] [5] [6] [7] [8] However, the clinical relevance and etiology of RS in MDS and MDS/MPN remain unclear due to the lack of specific molecular defects, including recurrent chromosomal abnormalities or mutations. High throughput-next generation sequencing (HT-NGS) is being widely used to identify mutational events in leukemia and other cancers. 9 We applied this technology to patients with various forms of MDS; using this approach, we found a somatic mutation in SF3B1, a gene located in chromosome 2q in a patient with RARS and high platelet counts. SF3B1, splicing factor 3b, subunit 1, is a component of the U2-small nuclear ribonucleoprotein (U2-snRNP) complex. U2-snRNP complex is one of the two unique spliceosomes present in eukaryotic cells. It consists of SF3b, SF3a and U2-snRNP-specific proteins. 10 Approximately 95% of messenger RNAs (mRNAs) have intronic regions that require further modification by spliceosomes to produce normal mRNAs. Aberrant splicing and mutations of these splicing mechanisms have been described in cancer.
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The current study describes recurrent mutations of a novel gene, SF3B1 in RARS. Study samples from 14 patients with RARS, 18 patients with RARS-T and 24 patients with similar morphologic features but without RS were analyzed. We applied the HT-NGS technology to interrogate the genome of a group of 11 MDS patients with various pathomorphologic features including patients with RARS-T, CMML-1, RAEB-1/2, RCMD and AML. In a patient with RARS-T, we found a possible candidate gene, SF3B1, an integral member of the spliceosome complex (patient no. 13; Table 1 and Figure 2b) . A specific missense mutation at amino-acid position 700 was detected, which resulted in the substitution of glutamic acid for lysine (K700E) (Figure 1a) . The somatic nature of this mutation was confirmed by sequencing non-clonal CD3 þ cells by Sanger method (Figure 1b) . Analysis of the other 10 patients studied by HT-NGS did not reveal any clonal SF3B1 sequence alterations. None of these patients showed RS except one with o15% RS. Based on this finding, we decided to focus on a larger cohort of patients with RARS. We found that 9/14 (64%) patients with RARS and 13/18 (72%) patients with RARS-T have mutations in SF3B1 (Figure 2a) . Clinical and molecular features of mutant cases are summarized in Table 1 . Of note is that, SF3B1 mutations were all heterozygous, and 50% of patients with RARS and 44% of patients with RARS-T harbor a common missense mutation, K700E, already reported in pancreatic tumor cells (http://www.sanger.ac.uk), and detected by the HT-NGS in the index case (patient no. 13, Table 1 ). All other mutations were novel, and the somatic nature was confirmed in non-clonal CD3 þ cells (Figure 1c) . Two mutations (R625L, patient no. 12 and R625C, patient no. 15) ( Table 1) could not be confirmed due to a lack of germline DNA, but they were absent in normal controls and in SNP databases. We also screened SF3B1 in a heterogeneous group of 24 patients with MDS and MPN without RS, and o15% RS finding no mutation in SF3B1 (Figure 2a) .
